- Home
- APLM vs TTNP Comparison
APLM vs TTNP Comparison
Compare APLM & TTNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- TTNP
- Stock Information
- Founded
- APLM 2016
- TTNP 1991
- Country
- APLM United States
- TTNP United States
- Employees
- APLM N/A
- TTNP N/A
- Industry
- APLM Blank Checks
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APLM Finance
- TTNP Health Care
- Exchange
- APLM Nasdaq
- TTNP Nasdaq
- Market Cap
- APLM 6.1M
- TTNP 5.4M
- IPO Year
- APLM N/A
- TTNP 1996
- Fundamental
- Price
- APLM $5.80
- TTNP $4.93
- Analyst Decision
- APLM
- TTNP
- Analyst Count
- APLM 0
- TTNP 0
- Target Price
- APLM N/A
- TTNP N/A
- AVG Volume (30 Days)
- APLM 47.7K
- TTNP 48.5K
- Earning Date
- APLM 08-18-2025
- TTNP 08-18-2025
- Dividend Yield
- APLM N/A
- TTNP N/A
- EPS Growth
- APLM N/A
- TTNP N/A
- EPS
- APLM N/A
- TTNP N/A
- Revenue
- APLM $198,000.00
- TTNP N/A
- Revenue This Year
- APLM $415.15
- TTNP N/A
- Revenue Next Year
- APLM N/A
- TTNP N/A
- P/E Ratio
- APLM N/A
- TTNP N/A
- Revenue Growth
- APLM N/A
- TTNP N/A
- 52 Week Low
- APLM $4.47
- TTNP $3.03
- 52 Week High
- APLM $35.98
- TTNP $14.80
- Technical
- Relative Strength Index (RSI)
- APLM 47.28
- TTNP 63.76
- Support Level
- APLM $5.41
- TTNP $3.88
- Resistance Level
- APLM $6.38
- TTNP $4.00
- Average True Range (ATR)
- APLM 0.44
- TTNP 0.37
- MACD
- APLM -0.01
- TTNP 0.08
- Stochastic Oscillator
- APLM 31.20
- TTNP 78.85
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.